Improvement of endothelium-dependent vasodilations by SKA-31 and SKA-20, activators of small- and intermediate-conductance Ca 2+-activated K +-channels

Acta Physiologica

Volumn 203, Issue 1, 2011, Pages 117-126

  Hasenau, A L ^a   Nielsen, G ^b   Morisseau, C ^c   Hammock, B D ^c   Wulff, H ^d   Kohler R ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Endothelial dysfunction; Endothelium derived hyperpolarizing factor; KCa2.3; KCa3.1; Nitric oxide; Soluble epoxide hydrolase

Indexed keywords

ANTHRA(2,1 D)THIAZOL 2 AMINE; CALCIUM ACTIVATED POTASSIUM CHANNEL; EPOXIDE HYDROLASE; NAPHTHO(1,2 D)THIAZOL 2 YLAMINE; NITRIC OXIDE; TRANS 4 [4 (3 ADAMANTAN 1 YL UREIDO)CYCLOHEXYLOXY]BENZOIC ACID; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL CELL; ARTICLE; CALCIUM CONDUCTANCE; CAROTID ARTERY; CELL MEMBRANE POTENTIAL; CONTROLLED STUDY; DRUG EFFICACY; ELECTROPHYSIOLOGY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME INHIBITION; HYPERPOLARIZATION; MOUSE; MYOGRAPHY; NONHUMAN; PATCH CLAMP; POTASSIUM CONDUCTANCE; PRIORITY JOURNAL; SYNTHESIS; VASODILATATION;

ANIMALS; BENZOTHIAZOLES; CAROTID ARTERIES; ENDOTHELIUM, VASCULAR; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MICE; MICE, KNOCKOUT; PATCH-CLAMP TECHNIQUES; VASODILATION;

EID: 80051669926     PISSN: 17481708     EISSN: 17481716     Source Type: Journal    
DOI: 10.1111/j.1748-1716.2010.02240.x     Document Type: Article

References (35)

1. Archer, S.L., Gragasin, F.S., Wu, X., Wang, S., McMurtry, S., Kim, D.H., Platonov, M., Koshal, A., Hashimoto, K., Campbell, W.B., Falck, J.R. & Michelakis, E.D. 2003. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11, 12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation 107, 769-776.
2. Brähler, S., Kaistha, A., Schmidt, V.J., Wolfle, S.E., Busch, C., Kaistha, B.P., Kacik, M., Hasenau, A.L., Grgic, I., Si, H. et al. 2009. Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation 119, 2323-2332.
3. Brondum, E., Kold-Petersen, H., Simonsen, U. & Aalkjaer, C. 2009. NS309 restores EDHF-type relaxation in mesenteric small arteries from type 2 diabetic ZDF rats. Br J Pharmacol 159, 154-165.
4. Campbell, W.B. & Fleming, I. 2010. Epoxyeicosatrienoic acids and endothelium-dependent responses. Pflugers Arch 459, 881-895.
5. Chiamvimonvat, N., Ho, C.M., Tsai, H.J. & Hammock, B.D. 2007. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol 50, 225-237.
6. + channel. Am J Physiol 271, L775-L784.
7. Ding, H., Hashem, M., Wiehler, W.B., Lau, W., Martin, J., Reid, J. & Triggle, C. 2005. Endothelial dysfunction in the streptozotocin-induced diabetic apoE-deficient mouse. Br J Pharmacol 146, 1110-1118.
8. Domino, E.F., Unna, K.R. & Kerwin, J. 1952. Pharmacological properties of benzazoles. I. Relationship between structure and paralyzing action. J Pharmacol Exp Ther 105, 486-497.
9. + is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 396, 269-272.
10. Edwards, G., Feletou, M. & Weston, A.H. 2010. Endothelium-derived hyperpolarising factors and associated pathways: a synopsis. Pflugers Arch 459, 863-879.
11. Feletou, M. & Vanhoutte, P.M. 2006. Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler Thromb Vasc Biol 26, 1215-1225.
12. Feletou, M., Köhler, R. & Vanhoutte, P.M. 2010. Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets. Curr Hypertens Rep 12, 267-275.
13. Feng, J., Liu, Y., Clements, R.T., Sodha, N.R., Khabbaz, K.R., Senthilnathan, V., Nishimura, K.K., Alper, S.L. & Sellke, F.W. 2008. Calcium-activated potassium channels contribute to human coronary microvascular dysfunction after cardioplegic arrest. Circulation 118, S46-S51.
14. Fleming, I., Rueben, A., Popp, R., Fisslthaler, B., Schrodt, S., Sander, A., Haendeler, J., Falck, J.R., Morisseau, C., Hammock, B.D. & Busse, R. 2007. Epoxyeicosatrienoic acids regulate Trp channel dependent Ca2+ signaling and hyperpolarization in endothelial cells. Arterioscler Thromb Vasc Biol 27, 2612-2618.
15. Furchgott, R.F. & Zawadzki, J.V. 1980. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373-376.
16. + channels in normal and impaired EDHF-dilator responses - relevance to cardiovascular pathologies and drug discovery. Br J Pharmacol 157, 509-526.
17. Hercule, H.C., Schunck, W.H., Gross, V., Seringer, J., Leung, F.P., Weldon, S.M., da Costa Goncalves, A., Huang, Y., Luft, F.C. & Gollasch, M. 2009. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol 29, 54-60.
18. Hwang, S.H., Tsai, H.J., Liu, J.Y., Morisseau, C. & Hammock, B.D. 2007. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 50, 3825-3840.
19. Imig, J.D. & Hammock, B.D. 2009. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8, 794-805.
20. +-channel transgenic mice. Pflugers Arch 459, 969-976.
21. Köhler, R., Kaistha, B.P. & Wulff, H. 2010. Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease. Expert Opin Ther Targets 14, 143-155.
22. Larsen, B.T., Miura, H., Hatoum, O.A., Campbell, W.B., Hammock, B.D., Zeldin, D.C., Falck, J.R. & Gutterman, D.D. 2006. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol 290, H491-H499.
23. Liu, Y., Sellke, E.W., Feng, J., Clements, R.T., Sodha, N.R., Khabbaz, K.R., Senthilnathan, V., Alper, S.L. & Sellke, F.W. 2008. Calcium-activated potassium channels contribute to human skeletal muscle microvascular endothelial dysfunction related to cardiopulmonary bypass. Surgery 144, 239-244.
24. + channel SK3 and connexin40 in arteriolar dilations during skeletal muscle contraction. FASEB J 24, 3572-3579.
25. Palmer, R.M., Ferrige, A.G. & Moncada, S. 1987. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327, 524-526.
26. Sankaranarayanan, A., Raman, G., Busch, C., Schultz, T., Zimin, P.I., Hoyer, J., Köhler, R. & Wulff, H. 2009. Naphtho[1, 2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol 75, 281-295.
27. Schmidt, K., Dubrovska, G., Nielsen, G., Fesus, G., Uhrenholt, T.R., Hansen, P.B., Gudermann, T., Dietrich, A., Gollasch, M., De Wit, C. & Kohler, R. 2010. Amplification of EDHF-type vasodilatations in TRPC1-deficient mice. Br J Pharmacol 161, 1722-1733.
28. + channel. Circ Res 99, 537-544.
29. Simpkins, A.N., Rudic, R.D., Schreihofer, D.A., Roy, S., Manhiani, M., Tsai, H.J., Hammock, B.D. & Imig, J.D. 2009. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol 174, 2086-2095.
30. + channels by NS309 (6, 7-dichloro-1H-indole-2, 3-dione 3-oxime). Biochim Biophys Acta 1665, 1-5.
31. + (SK3) channels modulates arterial tone and blood pressure. Circ Res 93, 124-131.
32. Vanhoutte, P.M. & Tang, E.H. 2008. Endothelium-dependent contractions: when a good guy turns bad!. J Physiol 586, 5295-5304.
33. Vanhoutte, P.M., Shimokawa, H., Tang, E.H. & Feletou, M. 2009. Endothelial dysfunction and vascular disease. Acta Physiol (Oxf) 196, 193-222.
34. Wang, Y.X., Ulu, A., Zhang, L.N. & Hammock, B. 2010. Soluble epoxide hydrolase in atherosclerosis. Curr Atheroscler Rep 12, 174-183.
35. Wong, S.L., Leung, F.P., Lau, C.W., Au, C.L., Yung, L.M., Yao, X., Chen, Z.Y., Vanhoutte, P.M., Gollasch, M. & Huang, Y. 2009. Cyclooxygenase-2-derived prostaglandin F2alpha mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. Circ Res 104, 228-235.